Invasive Breast Lobular Carcinoma clinical trials
8 active trials name this condition. Describe your situation to see which ones look like a fit.
By location
- A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer
- IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma
- Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
- Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
- [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
- Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer
- Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Invasive Breast Lobular Carcinoma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.